Kidney Cancer Coverage from Every Angle

Sumanta K. Pal, MD, on Using Tivozanib to Treat Progression of Kidney Cancer: Practical Information From the TIVO-3 Trial

Posted: Thursday, March 18, 2021

Sumanta K. Pal, MD, of City of Hope, offers some practical information for treating patients with advanced renal cell carcinoma that has progressed after multiple lines of therapy. Based on findings from the TIVO-3 study, tivozanib improved progression-free survival vs sorafenib and may prove to be a new standard of treatment.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.